PAI
SRPT icon

Palo Alto Investors’s Sarepta Therapeutics SRPT Stock Holding History

Palo Alto Investors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-210,258
Closed -$13.4M – 48
2025
Q1 		$13.4M Hold
210,258
– – 2.56% 12
2024
Q4 		$25.6M Hold
210,258
– – 3.96% 8
2024
Q3 		$26.3M Buy
210,258
+8,575
+4% +$1.19M 3.41% 12
2024
Q2 		$31.9M Buy
201,683
+418
+0.2% +$53.7K 3.69% 10
2024
Q1 		$26.1M Buy
201,265
+360
+0.2% +$44.1K 2.94% 11
2023
Q4 		$19.4M Buy
200,905
+106,875
+114% +$10.3M 1.75% 13
2023
Q3 		$11.4M Hold
94,030
– – 1.08% 14
2023
Q2 		$10.8M Buy
+94,030
New +$12.1M 0.87% 16

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Palo Alto Investors's SRPT Position: Q2 2025 in Review

Palo Alto Investors sold out of Sarepta Therapeutics (SRPT) in Q2 2025, closing a stake of 210,258 shares — an estimated $13.4M sold.

Palo Alto Investors first reported a position in SRPT in Q2 2023 and held it in 8 quarters. The position peaked at $31.9M in Q2 2024. 363 funds tracked by Wall St. Rank hold SRPT as of Q2 2025.

  • Palo Alto Investors reported no remaining Sarepta Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Palo Alto Investors sold 210,258 Sarepta Therapeutics shares in Q2 2025, an estimated $13.4M.
  • Palo Alto Investors first reported a position in Sarepta Therapeutics in Q2 2023 and held it in 8 quarters.
  • Palo Alto Investors's Sarepta Therapeutics position peaked at $31.9M in Q2 2024.
  • 363 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2025.

Based on Palo Alto Investors's 13F filing for Q2 2025, filed 14 Aug 2025.